{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreif7x2hkpdbrbpnrbn65nl7ydi3ctaji26uov5mhsi5x3w4j7dz3yq",
    "uri": "at://did:plc:p3227y2hdjlcc64d55t4c5y4/app.bsky.feed.post/3mlvhaqxgozt2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigy6mxsoa3c5dp7whssntn6ydmahpgdpygsgpgrxkmnlcmklbndsa"
    },
    "mimeType": "image/jpeg",
    "size": 255685
  },
  "path": "/2026/05/15/the-fdas-new-psychedelic-rules-are-groovy-but-the-agency-is-still-a-bad-trip/",
  "publishedAt": "2026-05-15T11:30:54.000Z",
  "site": "https://reason.com",
  "tags": [
    "Addiction",
    "Drug Legalization",
    "Drug Policy",
    "Medicine",
    "Psychedelics",
    "War on Drugs",
    "Department of Health and Human Services",
    "FDA",
    "Psilocybin",
    "Regulation",
    "Trump Administration"
  ],
  "textContent": "Psychedelic mushrooms, with the FDA logo in the corner",
  "title": "The FDA's New Psychedelic Rules Are Groovy, but the Agency Is Still a Bad Trip"
}